$IPSC

Carr Douglas sold $4K of IPSC

Carr Douglas (SVP Finance & Operations) sold 1,654 shares of Century Therapeutics, Inc. (IPSC) at $2.23 on 2026-06-12.

Original reporting
SEC EDGAR · Carr Douglas
Published Jun 15, 2026, 11:56 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 15, 2026, 11:58 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IPSC
Neutral
high confidence
Mentioned
$IPSC
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IPSCNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (shares, price, date) by an officer; it may marginally influence sentiment but does not provide new operating or financial information.

02

Market read

Traders may monitor for follow-on insider activity, but this filing alone is unlikely to drive a major repricing.

03

What to watch

Single small sale size and lack of disclosed reason mean traders should avoid extrapolating broader guidance or trial/product changes from this filing alone.

Relevance 3/10Novelty 5/10Timing: Filed 2026-06-15 for a sale executed 2026-06-12

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Century Therapeutics, Inc.

Company-level read

Ticker impact

$IPSCNeutralHigh confidence
Context

SEC Form 4 shows Carr Douglas (SVP Finance & Operations) sold 1,654 shares of Century Therapeutics at $2.2320 on 2026-06-12.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted unless part of a broader selling pattern.

Evidence & confidence

The filing is a Form 4 insider transaction with no 10b5-1 plan and no accompanying fundamental catalyst disclosed in the text.

Market effects

No sector read-through; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Without a 10b5-1 plan, the sale could reflect liquidity/tax needs rather than bearish fundamentals; impact may be overstated.

Key entities

  • Century Therapeutics, Inc.

    Company whose shares were sold by an officer in the reported Form 4 transaction.

  • Carr Douglas

    SVP Finance & Operations who executed the open-market sale.

Related articles

$AZNMed

Biotech and Pharma Industry News | BioPharma Dive

BioPharma Dive roundup covers AstraZeneca’s eplontersen failure in a major heart disease study, boosting expectations for rival TTR amyloidosis drugs from Alnylam and BridgeBio. Other items include ARPA-H funding, GSK ending a neuroscience alliance with Alector, Vera Therapeutics’ FDA nod for IgA nephropathy, and Vertex’s $10B plan to buy Crinetics.

$IPSCMedAI 8/10

New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026

Century Therapeutics (NASDAQ: IPSC) presented new preclinical results for CNTY-813, an iPSC-derived islet replacement engineered with Allo-Evasion™ 5.0, at ADA 2026. The company said transplanted cells maintained normoglycemia for over eight months in mice, with glucose normalization within 60 minutes in glucose tolerance tests. It also reported >50% beta-cell composition, no tumorigenesis in >140 mice, and immune evasion in humanized models without immunosuppression. Century said Phase 1 manufa